Abstract
Recently, induced pluripotent stem cells (iPSCs) were established as promising cell sources for revolutionary regenerative therapies. The initial culture system used for iPSC generation needed fetal calf serum in the culture medium and mouse embryonic fibroblast as a feeder layer, both of which could possibly transfer unknown exogenous antigens and pathogens into the iPSC population. Therefore, the development of culture systems designed to minimize such potential risks has become increasingly vital for future applications of iPSCs for clinical use. On another front, although donor cell types for generating iPSCs are wide-ranging, T cells have attracted attention as unique cell sources for iPSCs generation because T cell-derived iPSCs (TiPSCs) have a unique monoclonal T cell receptor genomic rearrangement that enables their differentiation into antigen-specific T cells, which can be applied to novel immunotherapies. In the present study, we generated transgene-free human TiPSCs using a combination of activated human T cells and Sendai virus under defined culture conditions. These TiPSCs expressed pluripotent markers by quantitative PCR and immunostaining, had a normal karyotype, and were capable of differentiating into cells from all three germ layers. This method of TiPSCs generation is more suitable for the therapeutic application of iPSC technology because it lowers the risks associated with the presence of undefined, animal-derived feeder cells and serum. Therefore this work will lead to establishment of safer iPSCs and extended clinical application.
Introduction
Induced pluripotent stem cells (iPSCs) are expected to provide new cell sources for revolutionary therapies[1]. In initial studies of generating human iPSCs, human fibroblasts were reprogrammed using forced expression of reprogramming factors[2]. Further studies subsequently showed successful reprogramming of several types of human somatic cells[3]. A range of donor cell types has been used to generate iPSCs; however, blood cells have attracted much of the attention because of the ease of sampling. Of these, T cells are a unique cell source for the generation of iPSCs because T cell-derived iPSCs (TiPSCs) have monoclonal T cell receptor (TCR) gene rearrangements in their genomes[4]–[7] and they can be differentiated into antigen-specific T cells for use in novel immunotherapy[8], [9]. Furthermore, clones and descendants of TiPSCs can be identified via the unique rearrangement patterns in the TCR gene locus[5].
Human T cells have been successfully reprogrammed with the exogenous expression of four transcription factors, OCT3/4, SOX2, KLF4, and c-MYC [4]–[7], [10]. Among these methods, Sendai virus (SeV) is an RNA virus of the Paramyxoviridae family that replicates in the cytoplasm and does not go through a DNA phase that can integrate into the host genome[11]–[13]. iPSCs generation using a combination of activated T cells and SeV has therefore showed benefit due to the high induction efficiency and lack of genome insertion of exogenous genes[5].
On another front, the application of culture systems to reduce potential risks of unpredictable agent becomes increasingly vital for applying iPSCs clinically[14]. The initial culture system for ESC generation used fetal calf serum in the culture medium and mouse embryonic fibroblast (MEF) as a feeder layer, introducing possibilities for transferring exogenous antigens, unknown viruses, or zoonotic pathogens to the generate cell populations[15]. An animal product-free medium that supports the derivation and long-term feeder-independent culture of human ESCs was recently developed[16], and in the field of iPSC generation, many efforts have been made to remove potentially harmful agents from the culture system[17]–[20].
Therefore, we investigated generating transgene-free human TiPSCs by applying a combination of SeV and activated T cells into defined culture medium and feeder-free conditions towards future clinical application of TiPSCs.
Materials and Methods
Cell Culture and SeV Infection
Blood samples were obtained from healthy donors. Samples were obtained only after the donors had provided written informed consent for blood sampling for the subsequent generation of iPSC. The handling these samples was approved by the Ethics Committee of Keio University (20-92-5). In addition, the study conformed to the principles outlined in the Declaration of Helsinki regarding the use of human tissue or subjects.
Peripheral blood mononuclear cells (PBMCs) were obtained from healthy donors (four men [31, 30, 30, and 31 years of age] and one 30-year-old woman) by the centrifugation of heparinized blood over a Ficoll-Paque PREMIUM (GE Healthcare) gradient, according to the manufacturer’s instructions. PBMCs were cultured at 37°C in 5% CO2 with plate-bound anti-CD3 monoclonal antibody (BD Pharmingen) in GT-T502 medium (KOHJIN BIO) that contained rIL-2 at 175 JRU/ml. After 5 days of culture, activated PBMCs were collected and transferred at 1.5×106 cells/well to a new 6-well plate coated with the anti-CD3 mAb, and incubated for an additional 24 hours. Then, cells were transduced with the CytoTune iPS Reprogramming Kit (DNAVEC) that contained SeV vectors individually encoding for each of OCT3/4, SOX2, KLF4, and c-MYC at an MOI of 10. After 24 hours of infection, the medium was changed to fresh GT-T502 medium. At 48 hours post-infection, the cells were collected and transferred to a 10 cm-dish coated with Matrigel (BD Biosciences) in mTeSR1 media (StemCell Technologies Inc.). After an additional 24 h incubation, the medium was changed to new mTeSR1 medium and was changed thereafter daily until the colonies were selected. The TiPSCs generated were also maintained on Matrigel in mTeSR1 medium. The mTeSR1 medium was changed every other day, and the cells were passaged using dissociation solution for human ES/iPS Cells (CTK solution, ReproCELL) every 6–7 days. M-TiPSCs1 and M-TiPSCs2 were derived from a 31 year old man. In this series of experiments, the human ESC line KhES-2 [21] was used as a positive control and was cultured using the same protocol as for the iPSC culture described above. The KhES-2 cells were obtained from the Department of Development and Differentiation, Institute for Frontier Medical Sciences (Kyoto University) and used in line with the Guidelines for Derivation and Utilization of Human Embryonic Stem Cells of the Ministry of Education, Culture, Sports, Science, and Technology, Japan.
ALP and Immunofluorescence Staining
ALP staining was performed with the ALP substrate (1-step NBT/BCIP; Pierce) after fixation with 4% paraformaldehyde (PFA; MUTO Pure Chemicals, Japan). Immunofluorescence staining was performed using the following primary antibodies: anti-NANOG (RCAB0003P, ReproCELL), anti-OCT3/4 (sc-5279, Santa Cruz), anti-SSEA 3 (MAB4303, Millipore), anti-SSEA 4 (MAB4304, Millipore), anti-Tra-1–60 (MAB4360, Millipore) and anti-Tra-1–81 (MAB4381, Millipore), anti-human smooth muscle actin (IR61161, DAKO), anti-human Sox17 (AF1924, R&D Systems), or anti-Nestin (N5413, Sigma). The fluorescence signals were detect using a conventional fluorescence laser microscope (IX70; Olympus) equipped with a color charge-coupled device (CCD) camera (CS220; Olympus). DAPI (Molecular Probes) and Hoechst (33342; Lonza) were used for nuclear staining. The secondary antibodies used were: anti-rabbit IgG and anti-mouse IgG and IgM conjugated with Alexa Fluor 488 or Alexa Fluor 568 (Molecular Probes).
Quantitative PCR Analysis
Total RNA samples were isolated using TRIZOL reagent (Invitrogen) and RNase-free DNase I (Qiagen), according to the manufacturer’s instructions. The concentration and purity of the RNA were determined using an ND-1000 spectrophotometer (Nanodrop), and the cDNA was synthesized using the Superscript First-Strand Synthesis System (Invitrogen). Quantitative PCR (QT-PCR) was performed using a 7500 real-time PCR system (Applied Biosystems), with SYBR Premix ExTaq (Takara, Otsu, Japan). The amount of mRNA was normalized against that of GAPDH mRNA. Primer sequences and cycling conditions are listed in Table S1.
Bisulfite Sequencing
Genomic DNA was isolated from bulk cell culture samples or undifferentiated colonies. A total of 5 µg DNA was used as the input for bisulfite conversion with EZ DNA Methylation-Gold Kit (ZYMO RESEARCH) according to the manufacturer’s protocol. The converted DNA was used as a template for conventional nested PCR to amplify the regions of the OCT3/4 and NANOG promoters[22]. The primers were specific for conversion of the sense DNA strands (Table.S1). The purified PCR products were TA-cloned into the pGEM-T vector (Promega), and insert sequences of randomly picked clones were analyzed using the ABI 3700 DNA analyzer (Applied Biosystems).
Analysis of TCR Gene Rearrangement in Genomic DNA
Genomic DNA was extracted from approximately 5×106 cells using a QIAamp DNA mini kit (QIAGEN) according to the manufacturer’s instructions. For TCRB gene rearrangement analysis, PCR was performed according to BIOMED-2 protocols[23]. The dominant band within the expected size range was purified using a Wizard SV Gel and PCR Clean-Up System (Promega) and the purified PCR products were TA-cloned into the pGEM-T vector (Promega). The insert sequences of randomly picked clones were analyzed using the ABI 3700 DNA analyzer (Applied Biosystems). V, D, and J segment usages were identified by comparison to the ImMunoGeneTics (IMGT) database (http://www.imgt.org/) and by using an online tool (IMGT/V-QUEST) [24]. Gene-segment nomenclature follows IMGT usage.
Global Gene Expression Analysis
For transcriptional profiling, total RNA was isolated from TiPSCs using the RNeasy Mini Kit (Qiagen). Cyanine-labeled antisense RNA was amplified using the Quick Amp Labeling Kit (Agilent), hybridized with the Gene Expression Hybridization Kit onto a Whole Human Genome Oligo Microarray (Agilent), and analyzed using the Agilent Microarray Scanner. The data were analyzed with the GeneSpring GX12.0 software (Agilent). Two normalization procedures were applied. Initially, the signal intensities with values less than 1 were assigned a value of 1. Then, each chip was normalized to the 50th percentile of the measurements taken from that chip. Finally, each gene was normalized to the median of that gene in the respective controls, to enable comparisons of relative changes in gene expression levels between different conditions. The microarray data in this experiment have been deposited in GEO and given the series accession number GSE56234.
Teratoma Formation
TiPSCs (at a concentration corresponding to 25% of the cells from a confluent 150-mm dish per mouse) were injected into the testis of SCID mice (CLEA, Japan). Prior to injection, mice were anesthetized using a mixture of ketamine (50 mg/kg), xylazine (10 mg/kg), and chlorpromazine (1.25 mg/kg). Adequate anesthesia was maintained by monitoring the heart rate, muscle relaxation, and loss of a sensory reflex response (i.e. no response to tail pinching) in mice. At around 8 weeks after injection, mice were killed by cervical dislocation and the teratomas were dissected, fixed in 10% PFA overnight, and embedded in paraffin. The sections were stained with hematoxylin and eosin. All experiments were performed in accordance with the Keio University Animal Care Guidelines and were approved by the Ethics Committee of Keio University (20-041-4), which conforms to the Guide for the Care and Use of Laboratory Animals published by the US National Institutes of Health (NIH Publication no. 85-23, revised 1996).
In vitro Differentiation
Cells were harvested using CTK solution (ReproCELL), and transferred to ultralow attachment plates (Corning) in hiPSC medium without bFGF. After 8 days, aggregated cells were plated onto gelatin-coated tissue culture dishes and incubated for an additional 8 days. The cells were incubated at 37°C in 5% CO2 and the medium was replaced every other day.
Chromosome Karyotyping
TiPSCs treated with colcemid solution (60 ng/ml) were cultured for 5 hours at 37°C to stop cell growth in metaphase. These cells were then incubated in 0.075 M KCl solution for 10 min at room temperature, followed by fixation in Carnoy’s solution. Fixed cells were sent to Nihon Gene Research Laboratories Inc. (Sendai, Japan) for analysis.
Results
Generation of Human TiPSCs under a Defined Culture Condition
First, we attempted to find a culture system involving alternatives to feeder cells in the generation of human TiPSCs. Previously, Matrigel[25], pronectin F[26], vitronectin[18], and CellStart[27] have been used as feeder cell substitutes for the successful culture of human pluripotent cells. Therefore we examined the feasibility of generating TiPSCs on these substitutes in a chemically defined culture medium, mTeSR1 or TeSR2. Activated human peripheral blood mononuclear cells (PBMCs) were infected with SeV vectors expressing OCT3/4, SOX2, KLF4, and c-MYC, and then replated onto feeder cells or one of the substitutes (Fig. 1A). Within 3 weeks of infection, we identified colonies that resembled human ESCs using mTeSR1 and Matrigel (Fig. 1B) or vitronectin. Although the efficiency was generally lower than culturing on feeder cell layers, the Matrigel and mTeSR1 combination resulted in higher efficiency than the other feeder-free conditions (Fig. 1C,1D), with successful iPSC generation from all donors (Fig. 1E). After picking these colonies on Day 25 from blood sampling, we established cell lines that maintained human ESC-like morphology.
Figure 1. Generation of human TiPSCs under defined conditions.
(A): Strategy used in the present study for reprogramming T cells. (B): Typical ESC-like TiPSC colony on day 25 after blood sampling under the defined culture condition. (C): Comparison of reprogramming efficiencies between the culture system using a feeder cell layer and that using defined culture conditions. Data show the mean ± s.d. (D): Comparison of representative 10-cm dishes stained for ALP (red spots) between feeder layer condition and defined culture condition (Matrigel) on day 25. (E): Comparison of reprogramming efficiencies between a culture system using a feeder cell layer and one using Matrigel and mTeSR1 medium for samples from five donors. Data show the mean ± s.d.
Characterization of TiPSCs Generated under a Defined Culture Condition
To confirm that these TiPSCs generated on Matrigel (M-TiPSCs) had the characteristics of typical ESCs and iPSCs, we analyzed stem cell marker expression at the protein and mRNA levels, by DNA chips, and with bisulfite sequencing of the NANOG and OCT3/4 promoters. Immunostaining and QT-PCR analyses revealed typical pluripotent marker expression in the M-TiPSCs (Fig. 2A,2B,2D, Fig.S1A). On the other hand, QT-PCR analysis showed no SeV transgene expression in the M-TiPSCs (Fig. 2C). Heat map and scatter plot analyses of human peripheral circulating T cells, ESCs, and M-TiPSCs showed that the global gene expression profiles of M-TiPSCs were overall similar to ESCs, and different from the parental human T cells (Fig. 2E, 2F). Bisulfite sequencing of M-TiPSCs showed that CpGs in the promoter regions of NANOG and OCT3/4 were predominantly unmethylated in the M-TiPSCs, as is the case in ESCs (Fig. 3A). Although previous reports have raised the possibility of leading chromosomal instabilities of human ESCs in feeder-free cultures [28], [29], G-band analysis in this study revealed that the M-TiPSCs had normal karyotypes (Fig. 3B). These results suggested that SeV-mediated gene transfer on our defined culture conditions successfully reprogrammed human T cells into iPSCs that are similar to ESCs.
Figure 2. Characterization of M-TiPSCs generated under a defined culture condition.
(A): ALP staining in M-TiPSCs. (B): QT-PCR analyses of M-TiPSCs for the ESC marker genes OCT3/4, NANOG, SOX2, KLF4, c-MYC, and TERT1. (C): QT-PCR analyses of M-TiPSCs for the transgenes, OCT3/4, SOX2, KLF4, and c-MYC. (D): Immunofluorescence staining for pluripotency and surface markers (NANOG, OCT3/4, SSEA3, SSEA4, TRA-1–60, and TRA-1–81) in M-TiPSCs1. (E): Heat map analyses of M-TiPSCs, ESCs, and the parental human T cells. (F): Scatter plots comparing the global gene expression profiles of M-TiPSCs with those of T cells and ESCs.
Figure 3. Analysis of TiPSCs genome modification and karyotype.
(A): Bisulfite sequencing analysis of the NANOG and OCT3/4 promoter regions in peripheral T cells, ESCs, and M-TiPSCs. Each row of circles for a given amplicon represents the methylation status of the CpG dinucleotides in one bacterial clone for that region. Open circles represent unmethylated CpGs and closed circles represent methylated CpGs. (B): G-band analysis for karyotypes of M-TiPSCs generated under a defined culture condition. M-TiPSCs1 and M-TiPSCs2 at passages 6 and 15, respectively, were used for G-band analysis. (C): Analysis of TCR rearrangements. V, D, and J segment usages in the TCRB gene locus were sequenced and identified by comparison to the international ImMunoGeneTics information system database. M-TiPSCs showed rearrangements of Vβ/Dβ1,2 and Dβ1,2/Jβ2.
Analysis of TCR Rearrangements
To confirm that the M-TiPSCs were derived from mature T cells, we analyzed the TCR rearrangements by sequencing the V, D, and J segment usages in the T-cell receptor beta (TCRB) gene locus. The specific rearrangement pattern identified in the TCRB gene locus of the M-TiPSCs (Fig. 3C) confirmed their mature T cell origins.
In vitro and In vivo Differentiation
To then demonstrate the pluripotency of our M-TiPSCs, we checked their differentiation capability. In vitro differentiation assays revealed M-TiPSC-generated embryoid bodies that contained derivatives of all three germ layers (Fig. 4A, Fig.S1B). In addition, M-TiPSCs injected into the testes of SCID mice gave rise to teratomas that contained derivatives of all three germ layers (Fig. 4B). These results indicate that the M-TiPSCs generated herein are pluripotent stem cells.
Figure 4. In vitro and in-TiPSCs.
(A): Immunofluorescence staining for Sox17 (endodermal marker), αSMA (mesodermal marker), and Nestin (ectodermal marker) in each TiPSCs1-derived differentiated cell in vitro. (B): Gross morphology of representative teratomas derived from TiPSCs1 in vivo (hematoxylin and eosin staining).
Discussion
In this report, we successfully generated iPSCs from human peripheral T cells without fetal calf serum in the culture medium and MEF as a feeder layer. These substrates are associated with the possibility of the transfer of exogenous antigens, unknown viruses, or zoonotic pathogens to the cell populations generated[15]. Although our protocol uses some substrates (e.g. Matrigel[30], anti-CD3 mAb, CTK solution[31], and SeV[32]) that are associated with a risk of transferring animal-derived pathogens, reducing the number of animal-derived substrates in the culture system will have a significant impact on the clinical application of iPSCs. However, the use of such products must be managed with strict quality control to avoid the risk of pathogen transfer and/or, in the future, these products should be removed from the protocol.
T cells are clinically suitable for iPSC generation because of their ease of sampling and culturing[5]. T cells have been successfully reprogrammed into a pluripotent state with retrovirus[7], [10], lentivirus[4], [6], or Sendai virus[5] using MEF feeder layers for the reprogramming culture conditions. Here, we report using a combination of SeV and activated T cells to successfully reprogram human T cells into a pluripotent state using defined culture conditions with verification of rearranged TCR genes. For clinical applications of iPSCs, establishment of such conditions are highly desirable for maximal safety and feasibility. Although reactivation of exogenous genes in the iPSCs still carries a risk of tumorigenesis[33], RNA-based vectors such as Sendai virus are much safer in this respect than DNA-based vectors, because they never integrate into a host genome[11]–[13]. The resultant feeder-independent TiPSCs thus have greatly enhanced safety for use in regenerative medicine.
Moreover TiPSCs have two unique features that are advantageous for clinical applications. First, because each TiPSC line contains a single rearranged TCR gene in its genome[4]–[7], they can be applied to novel immune therapy. Indeed, successful differentiation of human TiPSCs generated from antigen-specific T cells was reported[8], [9]. Second, the rearrangement patterns of T-cell receptor loci are readily traceable to identify the clonality and the descendants of TiPSCs without insertion of exogenous marker genes[5]. Therefore, generating human TiPSCs under a defined culture condition in which the potential risk of unpredictable agents is reduced, is valuable to extend applications of TiPSCs and is significant for implementing regenerative therapies using iPSCs.
In conclusion, we developed a method for safer iPSCs generation using Sendai virus and activated T cells under a defined culture condition for clinical use. This reprogramming system also provides advantages for the development of novel immune therapy and genetic markers for use as a clinical research tool for future applications of regenerative medicine.
Supporting Information
Characterization of M-TiPSCs2 generated under defined culture conditions. (A): ALP and immunofluorescence staining for pluripotency and surface markers (NANOG, OCT3/4, SSEA3, SSEA4, TRA-1–60, and TRA-1–81) in M-TiPSCs2. (B): Immunofluorescence staining for Sox17 (endodermal marker), αSMA (mesodermal marker), and Nestin (ectodermal marker) in each TiPSCs2-derived differentiated cell in vitro.
(TIF)
Oligonucleotide primers used for PCR.
(DOCX)
Acknowledgments
We thank Yoshiko Miyake, Sayaka Kanaami, Chihana Fujita, Miho Yamaguchi, Natsuko Henmi, and Rei Ohno from the Keio University School of Medicine for technical assistance.
Funding Statement
This work was partly supported by the Support Program to break the bottlenecks at R&D Systems for accelerating the practical use of Health Research Outcome, the Highway Program for the Realization of Regenerative Medicine, and a Grant-in-Aid for JSPS Fellows. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
References
- 1. Takahashi K, Yamanaka S (2006) Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 126: 663–676. [DOI] [PubMed] [Google Scholar]
- 2. Takahashi K, Tanabe K, Ohnuki M, Narita M, Ichisaka T, et al. (2007) Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 131: 861–872. [DOI] [PubMed] [Google Scholar]
- 3. Gonzalez F, Boue S, Izpisua Belmonte JC (2011) Methods for making induced pluripotent stem cells: reprogramming a la carte. Nat Rev Genet 12: 231–242. [DOI] [PubMed] [Google Scholar]
- 4. Staerk J, Dawlaty MM, Gao Q, Maetzel D, Hanna J, et al. (2010) Reprogramming of human peripheral blood cells to induced pluripotent stem cells. Cell Stem Cell 7: 20–24. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5. Seki T, Yuasa S, Oda M, Egashira T, Yae K, et al. (2010) Generation of induced pluripotent stem cells from human terminally differentiated circulating T cells. Cell Stem Cell 7: 11–14. [DOI] [PubMed] [Google Scholar]
- 6. Loh YH, Hartung O, Li H, Guo C, Sahalie JM, et al. (2010) Reprogramming of T cells from human peripheral blood. Cell Stem Cell 7: 15–19. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7. Brown ME, Rondon E, Rajesh D, Mack A, Lewis R, et al. (2010) Derivation of induced pluripotent stem cells from human peripheral blood T lymphocytes. PLoS One 5: e11373. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8. Vizcardo R, Masuda K, Yamada D, Ikawa T, Shimizu K, et al. (2013) Regeneration of human tumor antigen-specific T cells from iPSCs derived from mature CD8(+) T cells. Cell Stem Cell 12: 31–36. [DOI] [PubMed] [Google Scholar]
- 9. Nishimura T, Kaneko S, Kawana-Tachikawa A, Tajima Y, Goto H, et al. (2013) Generation of rejuvenated antigen-specific T cells by reprogramming to pluripotency and redifferentiation. Cell Stem Cell 12: 114–126. [DOI] [PubMed] [Google Scholar]
- 10. Kunisato A, Wakatsuki M, Shinba H, Ota T, Ishida I, et al. (2011) Direct generation of induced pluripotent stem cells from human nonmobilized blood. Stem Cells Dev 20: 159–168. [DOI] [PubMed] [Google Scholar]
- 11. Masaki I, Yonemitsu Y, Komori K, Ueno H, Nakashima Y, et al. (2001) Recombinant Sendai virus-mediated gene transfer to vasculature: a new class of efficient gene transfer vector to the vascular system. FASEB J 15: 1294–1296. [DOI] [PubMed] [Google Scholar]
- 12. Li HO, Zhu YF, Asakawa M, Kuma H, Hirata T, et al. (2000) A cytoplasmic RNA vector derived from nontransmissible Sendai virus with efficient gene transfer and expression. J Virol 74: 6564–6569. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 13. Ikeda Y, Yonemitsu Y, Sakamoto T, Ishibashi T, Ueno H, et al. (2002) Recombinant Sendai virus-mediated gene transfer into adult rat retinal tissue: efficient gene transfer by brief exposure. Exp Eye Res 75: 39–48. [DOI] [PubMed] [Google Scholar]
- 14. Sampsell-Barron T (2013) Xeno-free adaptation and culture of human pluripotent stem cells. Methods Mol Biol 1001: 81–97. [DOI] [PubMed] [Google Scholar]
- 15. Thomson JA, Itskovitz-Eldor J, Shapiro SS, Waknitz MA, Swiergiel JJ, et al. (1998) Embryonic stem cell lines derived from human blastocysts. Science 282: 1145–1147. [DOI] [PubMed] [Google Scholar]
- 16. Ludwig TE, Levenstein ME, Jones JM, Berggren WT, Mitchen ER, et al. (2006) Derivation of human embryonic stem cells in defined conditions. Nat Biotechnol 24: 185–187. [DOI] [PubMed] [Google Scholar]
- 17. Kim HT, Lee KI, Kim DW, Hwang DY (2013) An ECM-based culture system for the generation and maintenance of xeno-free human iPS cells. Biomaterials 34: 1041–1050. [DOI] [PubMed] [Google Scholar]
- 18. Chen G, Gulbranson DR, Hou Z, Bolin JM, Ruotti V, et al. (2011) Chemically defined conditions for human iPSC derivation and culture. Nat Methods 8: 424–429. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 19. Rodriguez-Piza I, Richaud-Patin Y, Vassena R, Gonzalez F, Barrero MJ, et al. (2010) Reprogramming of human fibroblasts to induced pluripotent stem cells under xeno-free conditions. Stem Cells 28: 36–44. [DOI] [PubMed] [Google Scholar]
- 20. Sugii S, Kida Y, Kawamura T, Suzuki J, Vassena R, et al. (2010) Human and mouse adipose-derived cells support feeder-independent induction of pluripotent stem cells. Proc Natl Acad Sci U S A 107: 3558–3563. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 21. Suemori H, Yasuchika K, Hasegawa K, Fujioka T, Tsuneyoshi N, et al. (2006) Efficient establishment of human embryonic stem cell lines and long-term maintenance with stable karyotype by enzymatic bulk passage. Biochem Biophys Res Commun 345: 926–932. [DOI] [PubMed] [Google Scholar]
- 22. Kim JB, Greber B, Arauzo-Bravo MJ, Meyer J, Park KI, et al. (2009) Direct reprogramming of human neural stem cells by OCT4. Nature 461: 649–643. [DOI] [PubMed] [Google Scholar]
- 23. van Dongen JJ, Langerak AW, Bruggemann M, Evans PA, Hummel M, et al. (2003) Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 Concerted Action BMH4-CT98-3936. Leukemia 17: 2257–2317. [DOI] [PubMed] [Google Scholar]
- 24. Giudicelli V, Brochet X, Lefranc MP (2011) IMGT/V-QUEST: IMGT standardized analysis of the immunoglobulin (IG) and T cell receptor (TR) nucleotide sequences. Cold Spring Harb Protoc 2011: 695–715. [DOI] [PubMed] [Google Scholar]
- 25. Mahlstedt MM, Anderson D, Sharp JS, McGilvray R, Munoz MD, et al. (2010) Maintenance of pluripotency in human embryonic stem cells cultured on a synthetic substrate in conditioned medium. Biotechnol Bioeng 105: 130–140. [DOI] [PubMed] [Google Scholar]
- 26. Sato H, Suemori H, Toguchida J, Iwata H (2007) Recombinant matrix protein for maintenance of undifferentiated primate embryonic stem cells. Tissue Eng 13: 1539–1547. [DOI] [PubMed] [Google Scholar]
- 27. Swistowski A, Peng J, Han Y, Swistowska AM, Rao MS, et al. (2009) Xeno-free defined conditions for culture of human embryonic stem cells, neural stem cells and dopaminergic neurons derived from them. PLoS One 4: e6233. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 28. Catalina P, Montes R, Ligero G, Sanchez L, de la Cueva T, et al. (2008) Human ESCs predisposition to karyotypic instability: Is a matter of culture adaptation or differential vulnerability among hESC lines due to inherent properties? Mol Cancer 7: 76. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 29. Draper JS, Smith K, Gokhale P, Moore HD, Maltby E, et al. (2004) Recurrent gain of chromosomes 17q and 12 in cultured human embryonic stem cells. Nat Biotechnol 22: 53–54. [DOI] [PubMed] [Google Scholar]
- 30. Emonard H, Grimaud JA, Nusgens B, Lapiere CM, Foidart JM (1987) Reconstituted basement-membrane matrix modulates fibroblast activities in vitro. J Cell Physiol 133: 95–102. [DOI] [PubMed] [Google Scholar]
- 31.Ohnuki M, Takahashi K, Yamanaka S (2009) Generation and characterization of human induced pluripotent stem cells. Curr Protoc Stem Cell Biol Chapter 4: Unit 4A 2. [DOI] [PubMed]
- 32. Fusaki N, Ban H, Nishiyama A, Saeki K, Hasegawa M (2009) Efficient induction of transgene-free human pluripotent stem cells using a vector based on Sendai virus, an RNA virus that does not integrate into the host genome. Proc Jpn Acad Ser B Phys Biol Sci 85: 348–362. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 33. Okita K, Ichisaka T, Yamanaka S (2007) Generation of germline-competent induced pluripotent stem cells. Nature 448: 313–317. [DOI] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
Supplementary Materials
Characterization of M-TiPSCs2 generated under defined culture conditions. (A): ALP and immunofluorescence staining for pluripotency and surface markers (NANOG, OCT3/4, SSEA3, SSEA4, TRA-1–60, and TRA-1–81) in M-TiPSCs2. (B): Immunofluorescence staining for Sox17 (endodermal marker), αSMA (mesodermal marker), and Nestin (ectodermal marker) in each TiPSCs2-derived differentiated cell in vitro.
(TIF)
Oligonucleotide primers used for PCR.
(DOCX)